成都中医药大学学报2017，Vol.40Issue(4)：37-40,4.DOI:10.13593/j.cnki.51-1501/r.2017.04.037
复方黄黛片灭活兔血清对人红白血病细胞增殖、凋亡及细胞周期的影响
Effects of Inactivated Rabbit Serum Containing Compound Realgar and Natural Indigo Tablet on Proliferation, Apoptosis and Cell Cycle of Human Erythroleukemia Cells
摘要
Abstract
Objective:To explore the effects of inactivated rabbit serum containing compound realgar and natural indigo tablet (CRNIT) on proliferation,apoptosis and cell cycle of HEL cells.Methods:The inactivated rabbit serum was prepared with CRNIT,hydroxyurea tablet and saline respectively and different concentrations of serum were used in cell culture.Then the cell proliferation toxicity was detected by CCK-8,and the cell apoptosis was detected by Annexin,V/PI staining and flow cytometry.Finally the cell cycle were analyzed by Cell Cycle Staining Kit and flow cytometry.Results:1.In certain range of serum concentration,the inhibitory effect on HEL cell proliferation was in a concentration-dependent manner in the CRNIT group,which was stronger than hydroxyurea tablet group and saline group (P ＜ 0.05);2.Comparing the inhibition rate of the HEL cells which were cultured with inactivated rabbit serum containing CRNIT at 24 h and 48 h,the inhibitory effect on HEL cells was in a time-dependent manner;3.In certain range of serum concentration,the promoting effect on HEL cell apoptosis was in a concentration-dependent manner in the CRNIT group,which was stronger than hydroxyurea tablet group and saline group (P ＜ 0.05);4.HEL cell number in G1 period increased significantly than the control well when it was cultured with inactivated rabbit serum containing CRNIT for 24 h.Conclusion:The inactivated rabbit serum containing CRNIT could effectively inhibit the proliferation,promote the early apoptosis and affect the cell cycle of HEL cells.关键词
HEL细胞/复方黄黛片/羟基脲/灭活血清Key words
HEL cell/CRNIT/Hydroxyurea/Inactivated serum分类
医药卫生引用本文复制引用
林双,韩凌,吴新忠,冯梅,卢爱丽,吴远彬,高红霞,李达,代喜平..复方黄黛片灭活兔血清对人红白血病细胞增殖、凋亡及细胞周期的影响[J].成都中医药大学学报,2017,40(4):37-40,4.基金项目
广东省科技计划项目(2013B021800231) （2013B021800231）
